en · de · es · fr · pt
tb-500-notes.peptides1004.com › Faq › Tb-500 Identity And Chemical Background — Research Overview

Tb-500 Identity And Chemical Background — Research Overview

By Editorial Desk · published 2026-04-05 · last reviewed 2026-04-20 · Faq

Ac-LKKTETQ is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.

TB-500 Identity and Chemical Background

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Handling, Stability and Analytical Detection

Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Tb-500 at a glance

PropertyValueNotes
Physical formLyophilised powderSealed vial; reconstituted before laboratory use
AppearanceWhite to off-white solidVisual descriptor used on certificates of analysis
Solubility classWater-solubleDissolves in water and aqueous buffers
Reported mass, fragmentNear 889 DaValue depends on the stated sequence
Reported mass, parent proteinNear 4963 Da43-residue thymosin beta-4

Handling, Storage and Analytical Checks

Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.

Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.

Related pages on this site

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Supporting material

==== Combinatorial probe anchor synthesis (cPAS) ==== This method is an upgraded modification to combinatorial probe anchor ligation technology (cPAL) described by Complete Genomics which has since become part of Chinese genomics company BGI in 2013. The two companies have refined the technology to allow for longer read lengths, reaction time reductions and faster time to results. In addition, data are now generated as contiguous full-length reads in the standard FASTQ file format and can be used as-is in most short-read-based bioinformatics analysis pipelines. The two technologies that form the basis for this high-throughput sequencing technology are DNA nanoballs (DNB) and patterned arrays for nanoball attachment to a solid surface. DNA nanoballs are simply formed by denaturing double stranded, adapter ligated libraries and ligating the forward strand only to a splint oligonucleotide to form a ssDNA circle. Faithful copies of the circles containing the DNA insert are produced utilizing Rolling Circle Amplification that generates approximately 300–500 copies. The long strand of ssDNA folds upon itself to produce a three-dimensional nanoball structure that is approximately 220 nm in diameter. Making DNBs replaces the need to generate PCR copies of the library on the flow cell and as such can remove large proportions of duplicate reads, adapter-adapter ligations and PCR induced errors.

The Matrix Revolutions begins immediately after the events of the second movie; as a result of his struggle with the sentinels, Neo returns to consciousness finding himself caught in an isolated train station-like limbo only accessible by order of the Merovingian, from which his mind is unable to free itself. It is here that he meets Sati, a young program created without a purpose, who is being smuggled into the Matrix by her parents, also programs in the machine world. Neo remains trapped until he is freed by Trinity (assisted by Morpheus and Seraph), who threatens the Merovingian in a Mexican standoff. After a final visit to the Oracle, Neo learns that he has powers over the machines which extend beyond the Matrix and that Smith is spreading, threatening to destroy both the Matrix and the real world. Building on the Oracle's previous explanations about the nature of choice, Neo learns that the Architect's assertion that his choice to save Trinity would inherently lead to the extinction of humankind was incorrect, due to his nature as a purely mathematical being rendering him incapable of seeing past choices made by humans, as he considers them mere variables in equations. Having told Neo that he now has the power to choose to end the war and defeat Smith, the Oracle then states "everything that has a beginning has an end, Neo" and informs him that in order for true peace to happen, he must travel to the heavily guarded Machine City in the real world and make a truce with the machines in order to save both races from extinction because of Smith's activities.

==== UPMC Salvator Mundi ==== UPMC Salvator Mundi International Hospital 75-bed private hospital in Rome, Italy, that is jointly owned by UPMC and Rome International Hospital Management Srl. UPMC owns a 50% stake in the hospital and leads its medical operations including having responsibility for selecting its medical director and chief operating officer.

In 1991, a group of Russian chemistry students discovered a simplified synthesis route which used phosgene instead of phenethylamine. Soon, abuse of the drug became widespread, causing a tenth of overdoses in the Moscow region.

Sources: en.wikipedia.org

Supporting material

18 September Scientists at CERN in Switzerland, using the ATLAS particle detector, observed quantum entanglement between quarks for the first time, and was also the highest-energy observation of entanglement so far. The largest known pair of astrophysical jets is discovered within the radio galaxy Porphyrion, extending 23 million light-years from end to end. This surpasses Alcyoneus, the previous record holder at 16 million light-years. 19 September – A recently discovered near-Earth object called 2024 PT5 is calculated to become a "mini-moon" with a temporary orbit around Earth from September 29 until November 25. It will return in the year 2055. 23 September Scientists publish the first multi-century, multi-model forecast of Antarctic Ice Sheet loss derived from global climate models, which indicates that the West Antarctic ice sheet may undergo a near-total collapse by 2300. Researchers demonstrate an asteroid deflection method using an X-ray pulse using a miniaturized mock asteroid for up to ~4 km diameter asteroids for which DART-like impacts are thought to be insufficient. 24 September – Researchers at ETH Zurich demonstrate an image-based AI model able to solve Google's reCAPTCHA v2, one of the world's most powerful tools for determining whether a user is human in order to deter bot attacks and spam. 30 September – Researchers develop a new method merging confocal fluorescence microscopy with microfluidic laminar flow, that can detect nanoparticles and viruses quickly. It can be achieved by using the 3D-printed microscopy approach, Brick-MIC.

Self-replicating "prion-like" amyloid assemblies of alpha-synuclein have been described that are invisible to the amyloid dye Thioflavin T and that can acutely spread in neurons in vitro and in vivo. Antibodies against alpha-synuclein have replaced antibodies against ubiquitin as the gold standard for immunostaining of Lewy bodies. The central panel in the figure to the right shows the major pathway for protein aggregation. Monomeric α-synuclein is natively unfolded in solution but can also bind to membranes in an α-helical form. It seems likely that these two species exist in equilibrium within the cell, although this is unproven. From in vitro work, it is clear that unfolded monomer can aggregate first into small oligomeric species that can be stabilized by β-sheet-like interactions and then into higher molecular weight insoluble fibrils. In a cellular context, there is some evidence that the presence of lipids can promote oligomer formation: α-synuclein can also form annular, pore-like structures that interact with membranes, allowing small molecules to be translocated from one side of the membrane to the other through the hollow oligomer. The deposition of α-synuclein into pathological structures such as Lewy bodies is probably a late event that occurs in some neurons. On the left hand side are some of the known modifiers of this process. Electrical activity in neurons changes the association of α-synuclein with vesicles and may also stimulate polo-like kinase 2 (PLK2), which has been shown to phosphorylate α-synuclein at Ser129.

As a result, the royalist cause began to collapse in the Americas. Over the course of the next decade, the Patriots' armies won major victories and obtained independence in their respective countries. Spain did not change the position against separatism, but the political instability in Spain, without a navy, army or treasury, convinced many Spanish Americans of the need to formally establish independence from the metropole. In Spain, a French army of the Holy Alliance invaded and supported the absolutists, restored Ferdinand VII, and occupied Spain until 1828.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.

Why do product listings show different sequences?

Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.

What is the reported molecular mass?

The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.

How should lyophilised peptide powder be stored?

Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.

Network